DigestRedComo funciona
Red
/
Empresas
Re
No verificado

ReCode Therapeutics

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

9 Comunicados de prensa

Ver todos los comunicados de prensa
17/11/2025
Industria
Ciencia
Biotecnología
Farmacéutica
Salud
Higiene alimentaria
Medicina - Varios
ReCode Therapeutics Initiates Enrollment of Phase 2 Clinical Trial of RCT2100 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis
Fuente
ReCode Therapeutics
Editor
Business Wire
1.00
0
29/09/2025
Mercado laboral
Eventos
Ciencia
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Sanidad
ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update
Fuente
ReCode Therapeutics
Editor
Business Wire
1.00
0
25/03/2025
Industria
Salud
Higiene alimentaria
Biotecnología
Medicina - Varios
Ciencia
Farmacéutica
ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT2100 for the Treatment of Cystic Fibrosis
Fuente
ReCode Therapeutics
Editor
Business Wire
1.00
0
18/11/2024
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Medicina - Varios
ReCode Therapeutics Announces Additional Funding From the Cystic Fibrosis Foundation to Accelerate Development of Novel Gene Correction Therapeutics to Treat Cystic Fibrosis
Fuente
ReCode Therapeutics
Editor
Business Wire
1.00
0
01/10/2024
Mercado laboral
Salud
Biotecnología
Ciencia
Sanidad
ReCode Announces Two Key Additions to Scientific Advisory Board
Fuente
ReCode Therapeutics
Editor
Business Wire
1.00
0
26/09/2024
Eventos
Industria
Biotecnología
Salud
Medicina - Varios
ReCode Therapeutics Presents Preclinical Data from its Cystic Fibrosis Program at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston
Fuente
ReCode Therapeutics
Editor
Business Wire
1.00
0
26/09/2024
Industria
Salud
Biotecnología
Medicina - Varios
Ciencia
Farmacéutica
ReCode Therapeutics Doses First Patient in Phase 1b Clinical Study of RCT2100 for the Treatment of Cystic Fibrosis
Fuente
ReCode Therapeutics
Editor
Business Wire
1.00
0
25/09/2024
Eventos
Salud
Biotecnología
Medicina - Varios
Ciencia
Farmacéutica
ReCode Therapeutics to Participate in Upcoming Investor Conferences
Fuente
ReCode Therapeutics
Editor
Business Wire
1.00
0
27/06/2024
Industria
Ciencia
Higiene alimentaria
Biotecnología
Medicina - Varios
Salud
Farmacéutica
Sanidad
ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia
Fuente
ReCode Therapeutics
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0